Company Prepares for Scientific Advice Meeting and Additional Upcoming

PR Newswire

MELBOURNE, Australia, April 19, 2016

MELBOURNE, Australia, April 19, 2016 /PRNewswire/ -- Propanc Health Group
Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare
company focusing on development of new and proprietary treatments for cancer
patients suffering from solid tumors such as pancreatic, ovarian and
colorectal cancers, today announced the filing of two more patent applications
in the United States regarding new compositions of its lead product, PRP, for
treating cancer.  The inventions summarize different combinations of the two
proenzymes, trypsinogen and chymotrypsinogen, which synergistically enhance
their anti-cancer effects, compared to when used in a one to one ratio, or as
singular agents.

Life-Changing Biotech (PRNewsFoto/Propanc Health Group Corporation)

The combinations are in addition to the preferred combination for PRP, and
supplements the Company's patent position across a broad range of cancers.

"When confirming PRP's effectiveness across a broad range of cancers, we also
confirmed a synergistic response between the two proenzymes to the majority of
cancer cell lines tested," said Dr Julian Kenyon, Propanc's Chief Scientific
Officer. "We also noticed that for some cancer types, more than one
combination proved to be effective, which we believe is patentable.  This is
extremely important, because it not only confirms the utility of our lead
product, PRP, for many different cancers, but also enables us to incorporate
other effective combinations as well.  In total, we now have five individual
patents covering PRP and also expect to file further divisional applications
in various jurisdictions.  We are extremely pleased with our progress as we
develop a robust portfolio as leaders in the field."

"Dr Kenyon and our team of researchers have done an excellent job in
continuing to grow and protect the Company's IP position," said James
Nathanielsz, Propanc's Chief Executive Officer. "New, potentially patentable
discoveries have also been made regarding the anti-cancer effects of
proenzymes which we believe could have significant implications in the cancer
treatment process.  We look forward to continuing to build on this research. 
Furthermore, we are now preparing for what is a significant period for the
Company as we turn our attention to the upcoming scientific advice meeting,
preparing orphan drug designation applications and developing a strategy to
engage licensing partners interested in our R&D programs, as we head towards
early stage patient trials."

The Company is soon to meet with the MHRA (Medicines and Healthcare Products
Regulatory Agency) to discuss formal preclinical and clinical development
activities for PRP.  Management also intends to apply for orphan drug
designation for pancreatic and ovarian cancers in the US and EU in the near
future as well, should they satisfy the necessary criteria.

The Company aims to fast track the development of proenzyme related oncology
products into clinical trials initially for pancreatic and ovarian cancers,
followed by colorectal cancer. According to Global Analyst Reports, the
combined world market for pancreatic, ovarian and colorectal cancers are
expected to reach over $12 billion by 2020.

About Propanc:
Propanc is developing new cancer treatments for patients suffering from
pancreatic, ovarian and colorectal cancers. We have developed a formulation of
anti-cancer compounds which exert a number of effects designed to control or
prevent tumors from recurring and spreading throughout the body. Our products
involve or employ proenzymes, which are inactive precursors of enzymes.

In the near term, we intend to target patients with limited remaining
therapeutic options for the treatment of solid tumors. In future, we intend to
develop our lead product to treat (i) early stage cancer and (ii)
pre-cancerous diseases and (iii) as a preventative measure for patients at
risk of developing cancer based on genetic screening.  For more information,

Forward-looking Statements:
Certain of the matters discussed in this announcement involve risks and
uncertainties  including, without limitation, those regarding the Company's
ability to establish and maintain the proprietary nature of its  technology
through the patent process, its ability to license from others patents and
patent applications, if necessary, to develop certain products, its ability to
implement its long range business plan for various applications of its
technology, and its ability to enter into agreements with any necessary
marketing and/or distribution partners for purposes of commercialization. This
is not a solicitation to buy or sell securities and does not purport to be an
analysis of the company's financial position.  See Propanc's most recent
Quarterly Report on Form 10-Q and related 8K filings.

Logo -

To view the original version on PR Newswire,